Popular Stop-Smoking Drugs to Carry Mental Health Risk Warnings

The U.S. Food and Drug Administration said it will immediately require boxed warnings about the risk of serious neuropsychiatric symptoms on the packaging of two popular smoking cessation drugs -- varenicline (Chantix) and buproprion (Zyban, Wellbutrin and generics). Reports of behavioral changes, depressed mood, agitation, hostility and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA's adverse event reporting system. Throughout the marketing...Full Story
Commenting on this article is closed.